Aurinia Pharmaceuticals announced that the Patent Trial and Appeal Board of the United States’ Patent and Trademark Office has terminated the Inter Partes Review it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUPH:
- Aurinia announces allowance of new, refined method of use patent for LUPKYNIS
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia Pharmaceuticals backs FY23 net product revenue view $120M-$140M
- Aurinia Pharmaceuticals reports preliminary net FY22 revenue $134M
- Aurinia Pharmaceuticals reports preliminary Q4 revenue $28.4M, consensus $26.97M